


## AMENDMENTS TO THE CLAIMS

Kindly amend claim 23 as provided in the following Claims Listing.

### Claims Listing:

Claims 1-22 (Cancelled).

23. (Currently Amended) A method for the treatment of a pathology associated with the constriction of smooth muscle cells in a subject in need thereof, said method comprising administering to said subject a compound of formula (Ia):



in which:

- R<sub>1</sub> and R<sub>2</sub> represent a hydrogen atom,
- R<sub>5</sub> represents a hydrogen atom, or a linear or substituted alkyl group with 1 to 10 carbon atoms, ~~in particular a butyl group~~, or an ester of formula COOR' in which R' represents a linear or substituted alkyl group with 1 to 10 carbon atoms,
- Y represents an -OH, -SH, or -NH<sub>2</sub> group,
- each of R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, and R<sub>10</sub> is, independently, ~~represent a hydrogen, atom, or at least one of R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, or R<sub>10</sub> represents a halogen atom selected from the group comprising a chlorine, bromine, or fluorine atom, and~~

- X represents an anion.

24. (Previously Presented) The method of claim 23, wherein said pathology is a vascular disorder.

25. (Previously Presented) The method of claim 24, wherein said pathology is arterial hypertension.

26. (Previously Presented) The method of claim 23, wherein said pathology is associated with bronchoconstriction.

27. (Previously Presented) The method of claim 26, wherein said pathology is asthma.


28. (Previously Presented) The method of claim 23, wherein X is chloride, bromide, or perchlorate.

29. (Previously Presented) The method of claim 23, wherein R<sub>5</sub> is a butyl group.


30. (Previously Presented) The method of claim 23, wherein R' is an ethyl group.

31. (Previously Presented) The method of claim 23, wherein said compound of formula (Ia) is selected from the following compounds:


**compound 13 (MPB-01)**




**compound 11 (MPB-26)**




**compound 14 (MPB-02)**




**compound 15 (MPB-03)**




**compound 16**




**compound 17**




**compound 24**




**compound 12 (MPB-05)**




**compound 18 (MPB-06)**




**compound 19 (MPB-07)**




**compound 20 (MPB-08)**




**compound 21 (MPB-27)**




**compound 25 (MPB-30)**




**compound 26 (MPB-29)**




**compound 27 (MPB-32)**




**compound MPB-91**




**compound MPB 73**




**compound MPB 75**




**compound MPB 86**




**compound MPB 77**




**compound MPB 87**




**compound MPB 88**



**compound MPB 102**




**compound MPB 103**




32. (Previously Presented) The method of claim 23, wherein said compound of formula (Ia) is MPB-07 of the following formula:

**compound 19 (MPB-07)**




33. (Previously Presented) The method of claim 23, wherein said compound of formula (Ia) is MPB-91 of the following formula:

**compound MPB-91**




34. (Previously Presented) A compound selected from:


**compound MPB 73**




**compound MPB 75**




**compound MPB 86**




**compound MPB 77**



**compound MPB 87**




**compound MPB 88**




35. (Previously Presented) A compound selected from:

**compound MPB 102**



**compound MPB 103**



36. (Previously Presented) A pharmaceutical composition comprising a compound of claim 34 in combination with a pharmaceutically acceptable carrier.

37. (Previously Presented) A pharmaceutical composition comprising a compound of claim 35 in combination with a pharmaceutically acceptable carrier.